Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal CancerPeter S Hall, Pavel Bezecny, Sebastian Cummins et al.|JAMA Oncology|2021Cited by 196
Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine TherapyJonathan Wadsley, Sarah Brown, Gemma Ainsworth et al.|Thyroid|2023Cited by 19
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinomaHannah Buckley, Naveen Vasudev, Fiona Collinson et al.|BMC Cancer|2019Cited by 17
Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)Naveen Vasudev, Thomas Powles, Gemma Ainsworth et al.|Journal of Clinical Oncology|2023Cited by 14
LBA29 Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM)Naveen Vasudev, T.B. Powles, Gemma Ainsworth et al.|Annals of Oncology|2021Cited by 9